A P450 enzyme for the synthesis of calcifediol
By mutation of Bacillus Sonora Desert P450 enzyme, the selectivity of its hydroxylation position is improved, and the problems of long routes, low yields and the use of toxic metals in the synthesis of existing calcitrol are solved, thus achieving efficient and economical Enzyme catalyzed the conversion of VD3 to calcitic glycol.
Patent Information
- Application Number
- CN202111098209.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-09-18
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2041-09-18
AI Technical Summary
The existing chemical synthesis methods of calcitrol have problems such as long routes, low yields, and the use of toxic and harmful heavy metals. The hydroxylation position of P450 enzyme in the enzyme catalytic method is insufficient, resulting in impurity of the product.
By screening and modifying the P450 enzyme from Bacillus Sonora Desert, improving its hydroxylation position selectivity through mutations, mutants such as K80F/T244A/F388V are constructed, enhancing their hydroxylation position specificity at C25 position and avoiding excessive hydroxyl groups change.
The purity and yield of calciferin is significantly improved, the production of other derivative compounds is reduced, the production cost is reduced, and the efficient conversion of enzyme-catalyzed VD3 to calciferin is achieved.
Smart Images

Figure CN115838695B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of enzyme catalysis, and in particular relates to a P450 enzyme mutant and its use in enzymatically catalyzing VD3 to produce calcifediol. Background Art
[0002] Calcifediol, also known as 25-OH vitamin D3 (abbreviated as 25(OH)VD3), is the first metabolically active substance of vitamin D3 (abbreviated as VD3) and the main metabolic form of VD3. Calcifediol is of great significance to human health and has a very positive therapeutic effect on certain diseases such as osteoporosis, osteomalacia, hyperglycemia, chronic kidney disease, etc. In addition, calcifediol also performs well as a feed additive for feeding poultry and some other farm animals, used to strengthen animal bones and reduce the mortality rate of newborn animals.
[0003] The chemical synthesis of calcifediol can be divided into two categories: total synthesis and semi-synthesis. Both methods generally have long synthesis routes (at least seven steps of reaction), which results in a very low yield of calcifediol. The total synthesis method refers to cutting the calcifediol molecule into two small molecules, and then splicing the two parts together by condensation or coupling. The semi-synthesis method refers to using a macromolecule such as a natural steroid compound or the core structure of vitamin D3 as a raw material, and then modifying the ring and side chain. Some of them also have to undergo photochemical ring opening to form calcifediol. The total synthesis method generally has a long synthesis route, low yield, and cumbersome operation, which is not suitable for industrial production applications. Among the semi-synthetic methods, Scherlitz-Hofmann[1] et al. reported a method for synthesizing the target product calcifediol using ergosterol as the starting material, and Fuse[2] et al. improved this method, simplified the steps, and also increased the yield to a certain extent, which is a significant improvement compared to the total synthesis method. However, in practical applications, there are still problems such as long synthesis routes, low total yield (30%), and the use of toxic and harmful heavy metal substances. Masato[3] et al. proposed a synthesis route using 5,7,24-triene cholesterol as the starting material. The yield of this method has been improved to a certain extent, but the process route is still too long; Shul'man[4] et al. improved this method, shortened the reaction steps, and improved the yield, but this method used highly toxic metal mercury, which greatly limited the scale-up of this method to practical application production. There is also a synthesis method using vitamin D2 as the starting material. This method has unique advantages because vitamin D2 has a similar structure to calcitriol, but the entire synthesis route is still long and requires multiple protection-deprotection reactions. The atom utilization rate is low, resulting in a low total yield.
[0004] The simplest and most direct way to synthesize calcifediol is to hydroxylate C25 of vitamin D3 and add an O atom to the CH bond. One of the most popular ways to achieve this process is to catalyze it through cytochrome P450 oxidase. Cytochrome P450 oxidase is also called P450 enzyme, monooxygenase, multifunctional oxidase, and hydroxylase. The natural function of this P450 enzyme is to catalyze the hydroxylation reaction of C25 of the substrate VD3 molecule with the participation of oxygen and NADPH as a cofactor. Compared with the chemical synthesis method, the enzyme-catalyzed reaction steps are simple. It uses vitamin D3 as the starting material and only needs one step of hydroxylation reaction to obtain calcifediol. It has the advantages of relatively high conversion rate, simple separation and purification process, mild reaction conditions, low cost, environmental friendliness, and no production of many toxic and harmful substances. Summary of the invention
[0005] In order to explore the economic feasibility of preparing calcifediol by catalyzing the hydroxylation of VD3 by P450 enzymes, we focused our research on the screening and improvement of P450 enzymes, including improving enzyme activity, substrate tolerance, and stability. By screening and comparing P450 enzymes from many biological sources, especially microbial sources, we found that the P450 enzyme from Bacillus sonorensis (named S1 in this article) has a particularly high enzyme activity in catalyzing the hydroxylation of VD3. However, due to its high enzyme activity, the conversion products of VD3 are complicated. It is not only converted into calcifediol (25(OH)VD3), but also continues to be converted into other hydroxylated products such as calcitriol (1α,25(OH)2VD3). That is, the P450 enzyme S1 lacks "hydroxylation position singularity" or "product specificity", resulting in the hydroxylation reaction not being "stopped at the right time" and over-hydroxylation.
[0006]
[0007] In order to make full use of its advantage of high enzyme activity in catalyzing VD3 reaction and overcome its low defect of hydroxylation position singleness (hydroxylation position specificity, hydroxylation position selectivity), we mutated the wild enzyme S1, established the S1 gene mutation library by error-prone PCR method, and then obtained a P450 enzyme with significantly improved hydroxylation position selectivity by screening the gene mutation library. Specifically, the present invention includes the following technical solutions:
[0008] A P450 enzyme mutant, which is a mutant formed by mutation of one or more, preferably two or more, more preferably three of the following sites in the amino acid sequence SEQ ID NO:1 of a wild-type P450 enzyme derived from Bacillus sonorensis: K80, T244, F388. The P450 enzyme mutant can convert VD3 only into calcifediol without further conversion into other hydroxylated products such as calcitriol.
[0009] The above term "mutation" includes but is not limited to substitution, deletion or addition of amino acids.
[0010] Preferably, the above mutation is selected from K80F, T244A, and F388V.
[0011] Preferably, the above-mentioned P450 enzyme mutant is a mutant formed by mutations at three sites, K80, T244 and F388.
[0012] More preferably, the P450 enzyme mutant is a K80F, T244A, F388V mutant of the wild enzyme SEQ ID NO: 1, numbered as M3 herein, and its amino acid sequence is SEQ ID NO: 3:
[0013] MAKSIQSGNRYANWIPMKEISSNEDQLFPFPIYNRLRKTSPVRYDQDRKCWDIFAYEDVQYVLKTPKLFSSKRGGDMEG F SILTMDPPRHTKMRAIVNKAFTPKTVKQLEAHIEEVTAFLLDEAKDKETFDMVEDLAGPLPVIIIAELLGVPTEDRRIFKHYSDILVSGAKDSSDEAIKQMNKQREEGSEFLRGYFKTIIEERKKDPKEDLISLLIQAEVEGERLTEDELLGFCTILLVAGNE A TTNLIANAVRYLTEDPKTQETVRGDLSLVPHLVEETLRYYPPVQAIGRIAAQDTDIKGVTIPKGSTIISWVASANRDETKFDDPEAFRLDRKSNPHMSFGFGIHFCLGAPLARLEANTALSYLLRHASIVREPSEKLEVIQSP V VFGVRRLPVRLLSQS (SEQ ID NO: 3).
[0014] The second aspect of the present invention provides a gene encoding the above-mentioned P450 enzyme mutant.
[0015] Preferably, the nucleotide sequence of the gene encoding the P450 enzyme mutant SEQ ID NO:3 may be SEQ ID NO:4.
[0016] The third aspect of the present invention provides a plasmid comprising the above gene. The plasmid comprises a vector for expressing the above gene, preferably a pET series or a pRSFDuet series, such as pET22b, pET24a, pET28a, pRSFDuet-1, etc., but is not limited thereto.
[0017] The fourth aspect of the present invention provides a microorganism for expressing the above-mentioned P450 enzyme mutant. For example, the microorganism is a transformant transformed with the above-mentioned plasmid.
[0018] The above-mentioned microorganism can be selected from Escherichia coli, Bacillus subtilis, Pichia pastoris, Saccharomyces cerevisiae, preferably Escherichia coli, more preferably Escherichia coli BL21 (DE3).
[0019] The fifth aspect of the present invention provides the use of the above-mentioned P450 enzyme mutant or the above-mentioned microorganism in the production of calcifediol.
[0020] Specifically, in the production of calcifediol, VD3 is used as a substrate raw material, and the above-mentioned P450 enzyme mutant or microorganism is used as a catalyst to catalyze the C25 hydroxylation reaction to obtain calcifediol.
[0021] Conventional process conditions can be used to produce calcifediol, for example, the reaction temperature is selected to be 20-35°C, preferably 25-30°C.
[0022] In a preferred embodiment, 2-hydroxypropyl-β-cyclodextrin can be added to the reaction system as a co-solvent, but organic solvents such as DMSO and ethanol are not used as co-solvents to avoid organic solvents inhibiting enzyme activity.
[0023] Preferably, the reaction system may also include a NADPH regeneration system to form a combined catalytic system, that is, the reaction system includes NADP + , glucose and glucose dehydrogenase (GDH) or NADP + , glucose 6-phosphate and glucose-6-phosphate dehydrogenase. During the reaction, glucose dehydrogenase catalyzes the oxidation of glucose and converts NADP + Reduced to NADPH.
[0024] Preferably, coenzymes FDR (ferredoxin reductase) and FDI (ferredoxin) can also be added to the reaction system. The addition of FDR and FDI can promote the hydroxylation reaction of VD3. The amino acid sequence of ferredoxin reductase FDR is:
[0025] MQIASDVEAPPPAPAKVEKHSKKMEEGITVNKFKPKTPYVGRCLLNTKITGDDAPGETWHMVFSHEGEIPYREGQSVGVIPDGEDKNGKPHKLRLYSIASSALGDFGDAKSVSLCVKRLIYTNDAGETIKGVCSNFLCDLKPGAEVKLTGPVGKEMLM PKDPNATIIMLGTGTGIAPFRSFLWKMFFEKHDDYKFNGLAWLFLGVPTSSSLLYKEEFEKMKEKAPDNFRLDFAVSREQTNEKGEKMYIQTRMAQYAVELWEMLKKDNTYFYMCGLKGMEKGIDDIMVSLAAAEGIDWIEYKRQLKKAEQWNVEVY.
[0026] The amino acid sequence of ferredoxin FDI is:
[0027] MAAYKVTLVTPTGNVEFQCPDDVYILDAAEEEGIDLPYSCRAGSCSSCAGKLKT GSLNQDDQSFLDDDQIDEGWVLTCAAYPVSDVTIETHKEEELTA.
[0028] Compared with the wild-type P450 enzyme SEQ ID NO: 1, the product specificity of the VD3 reaction catalyzed by the P450 enzyme mutant SEQ ID NO: 3 screened by the present invention is significantly improved, and the hydroxylation reaction of VD3 can only occur at the C25 position, but not at other positions such as the C1 position, thereby greatly improving the purity and yield of the target product calcifediol, avoiding the production of other derivative compounds such as calcitriol, and correspondingly reducing the post-processing steps, significantly reducing the production cost, and thus having significant economic significance. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 It is the HPLC chart of the P450 enzyme mutant M3 catalyzing the VD3 reaction.
[0030] Figure 2It is a HPLC comparison chart of the VD3 reaction catalyzed by the P450 enzyme mutant M3, mutant M4 and wild-type P450 enzyme, wherein the reference numeral 1 is calcifediol and 2 is calcitriol.
[0031] Figure 3 The HPLC comparison charts when 2-hydroxypropyl-β-cyclodextrin, DMSO and ethanol were added as co-solvents respectively when the P450 enzyme mutant M3 catalyzed the VD3 reaction. DETAILED DESCRIPTION
[0032] In order to screen a P450 enzyme with high enzyme activity that catalyzes the synthesis of calcifediol from vitamin D3, the inventors screened a large number of microbial sources through literature retrieval and database retrieval analysis, and compared the various P450 enzyme resources accumulated in the laboratory, and selected the P450 enzyme of Bacillus sonorensis, which was named S1, and its amino acid sequence is SEQ ID NO: 1:
[0033] MAKSIQSGNRYANWIPMKEISSNEDQLFPFPIYNRLRKTSPVRYDQDRKCWDIFAYEDVQYVLKTPKLFSSKRGGDMEGKSILTMDPPRHTKMRAIVNKAF TPKTVKQLEAHIEEVTAFLLDEAKDKETFDMVEDLAGPLPVIIIAELLGVPTEDRRIFKHYSDILVSGAKDSSDEAIKQMNKQREEGSEFLRGYFKTIIEER KKDPKEDLISLIQAEVEGERLTEDELLGFCTILLVAGNETTTNLIANAVRYLTEDPKTQETVRGDLSLVPHLVEETLRYYPPVQAIGRIAAQDTDIKGVTIPKGSTIISWVASANRDETKFDDPEAFRLDRKSNPHMSFGFGIHFCLGAPLARLEANTALSYLLRHASIVREPSEKLEVIQSPFVFGVRRLPVRLLSQS(SEQ ID NO:1).
[0034] The disadvantage of the wild-type P450 enzyme S1 is that the hydroxylation position specificity is low. When catalyzing the conversion of VD3, in addition to the hydroxylation reaction at the C25 position to produce calcifediol, it will continue to undergo hydroxylation at the C1 position to produce calcitriol, resulting in a mixed product state.
[0035] In order to solve this problem, the inventors tried to transform the wild-type P450 enzyme S1 to improve its hydroxylation position specificity, so that the hydroxylation reaction only occurs at the C25 position during VD3 conversion and does not continue to occur at other positions such as the C1 position. Therefore, using bioinformatics methods, a homology model of S1 was constructed, including a computer-simulated protein 3D model, and molecular docking with the substrate VD3 was performed. Combined with bioinformatics analysis, the hot amino acids in the active pocket and some amino acid sites that may interact were determined. Through rational analysis and semi-rational design, these amino acid sites were subjected to site-directed mutagenesis to construct a mutant library using the means of directed evolution. Finally, a K80F / T244A / F388V mutant was screened out, named M3 in this article, whose C25 position hydroxylation specificity is significantly higher than that of the wild type, and when it catalyzes VD3 conversion, it can almost obtain the only hydroxylated product calcifediol.
[0036] In addition, the inventors also tried to continue to transform the mutant M3 in order to improve its enzyme activity and maintain its C25 hydroxylation position specificity, so as to facilitate the industrial production of calcifediol. For example, amino acid substitution was performed at position 83. Threonine (T or Thr) was used to replace the original leucine (L or Leu), and a (K80F, L83T, T244A, F388V) mutant relative to the wild enzyme S1 was obtained, which greatly reduced the hydroxylation position specificity of M3, resulting in a hydroxylation reaction at the C1 position. When it catalyzed the conversion of VD3, the product of calcitriol reached more than 80%. In other words, the product specificity of M3 was changed, and it had a high degree of calcitriol selectivity, which was exactly the opposite of our expectations. The K80F / L83T / T244A / F388V mutant was named M4, and its amino acid sequence was SEQ ID NO: 5, which should have development and application potential in the industrial production of calcitriol.
[0037] In this article, the terms "wild type", "wild enzyme", and "wild-type enzyme" have the same meaning, and all refer to the P450 enzyme S1 with an amino acid sequence of SEQ ID NO: 1. Sometimes, for the sake of convenience, the wild-type P450 enzyme and its mutant M3, etc., may be collectively referred to as "P450 enzyme" in this article.
[0038] The mutations at some sites in the amino acid sequence of the wild enzyme are not single mutations, for example, the mutation at position 80 can be K80F, K80A or K80G, in which case it can be expressed as K80FAG. The K80F mutation refers to a mutation in which the residue lysine (K or Lys) at position 80 of the amino acid sequence of SEQ ID NO: 1 is replaced by phenylalanine (F or Phe), and so on.
[0039] The P450 enzyme mutant M3 of the present invention has only 403 amino acids and a clear structure, so those skilled in the art can easily obtain its encoding genes, expression cassettes and plasmids containing these genes, and transformants containing the plasmids.
[0040] These genes, expression cassettes, plasmids, and transformants can be obtained by genetic engineering construction methods well known to those skilled in the art.
[0041] As is known to all, the expression results of the same nucleotide sequence in different microbial hosts are often very different. In order to optimally express P450 enzymes or their mutants M3, etc. in Escherichia coli, which is most commonly used in genetic engineering, the expression genes of these enzymes can be codon optimized.
[0042] Codon optimization is a kind of technology that can be used for maximizing protein expression in organism by increasing the translation efficiency of gene of interest.Different organisms usually show the special preference for one of some codons of the same amino acid being encoded due to mutation tendency and natural selection.For example, in fast-growing microorganisms such as Escherichia coli, the optimization codon reflects the composition of its respective genome tRNA library.Therefore, in fast-growing microorganisms, the low-frequency codon of amino acid can be replaced with the codon for the same amino acid but with high frequency.Therefore, the expression of optimized DNA sequence is improved in fast-growing microorganisms.
[0043] For example, in order to express the P450 enzyme and its mutant M3 in E. coli, the coding gene of the codon-optimized wild P450 enzyme SEQ ID NO: 1 can be SEQ ID NO: 2; the coding gene of the P450 enzyme mutant SEQ ID NO: 3 can be SEQ ID NO: 4.
[0044] When expressing the P450 enzyme and its mutants M3 and M4 in Escherichia coli, the encoding gene can be cloned on an appropriate vector. In one embodiment, the encoding gene can be cloned on the plasmid pRSFDuet-FDR_FDI constructed by our research group, whose base sequence is SEQ ID NO:7, and the plasmid contains the encoding genes of ferredoxin reductase FDR and ferredoxin FDI.
[0045] The transformant host can be any microorganism suitable for expressing P450 enzymes, including bacteria and fungi. Preferably, the microorganism is Bacillus subtilis, Pichia pastoris, Saccharomyces cerevisiae, or Escherichia coli, preferably Escherichia coli, more preferably Escherichia coli BL21 (DE3).
[0046] When used as a biocatalyst for producing calcifediol, the P450 enzyme of the present invention can be in the form of an enzyme or a bacterial cell. The enzyme forms include free enzymes, immobilized enzymes, including purified enzymes, crude enzymes, fermentation broths, enzymes immobilized by carriers, etc.; the bacterial cell forms include living bacterial cells, dead bacterial cells, immobilized bacterial cells, etc.
[0047] The present invention is further described in detail below in conjunction with specific examples. It should be understood that the following examples are only used to illustrate the present invention and are not used to limit the scope of the present invention.
[0048] Example
[0049] This article involves the addition amount, content and concentration of various substances, and the percentages mentioned here refer to the mass percentages unless otherwise specified.
[0050] Materials and methods
[0051] The whole gene synthesis, primer synthesis and sequencing in the examples were all commissioned to Sangon Biotechnology Co., Ltd.
[0052] The molecular biology experiments in the embodiments include plasmid construction, enzyme digestion, ligation, competent cell preparation, transformation, culture medium preparation, etc., and are mainly carried out with reference to Molecular Cloning Experiment Guide (3rd edition), edited by J. Sambrook and DW Russell (USA), translated by Huang Peitang et al., Science Press, Beijing, 2002). If necessary, the specific experimental conditions can be determined by simple experiments.
[0053] PCR amplification experiments were performed according to the reaction conditions provided by the plasmid or DNA template supplier or the kit instructions. If necessary, adjustments could be made through simple experiments.
[0054] LB medium: 10g / L tryptone, 5g / L yeast extract, 10g / L sodium chloride, pH 7.2. (LB solid medium plus 20g / L agar powder.)
[0055] TB medium: 24g / L yeast extract, 12g / L tryptone, 16.43g / L K2HPO4.3H2O, 2.31g / L KH2PO4, 5g / L glycerol, pH 7.0-7.5. (TB solid medium plus 20g / L agar powder.)
[0056] 20X electroporation master solution: 80 g / L glycine, 2% Tween 80.
[0057] HPLC determination conditions of substrates VD3, calcifediol and calcitriol:
[0058] Instrument model: SHIMADZU LC-2030Plus; column model: YMC J'sphere ODS-H80; mobile phase: acetonitrile, ultrapure water; 0-12min: acetonitrile concentration increased from 50% to 100%; 12-18min: 100% acetonitrile; 18.01-20min: 50% acetonitrile; flow rate: 1.5mL / min; column temperature: 40℃; detection wavelength: 265nm; detection time: 20min; injection volume: 10μL; VD3 retention time: 14.983min; calcifediol retention time: 7.833min; calcitriol retention time: 8.410min.
[0059] It should be noted that, for the convenience of description, in the embodiments, the strain number, plasmid number, enzyme number, and enzyme encoding gene number may share one number, which is easy for those skilled in the art to understand, that is, the same number can refer to different biological forms in different environments. For example, S1 can represent a wild P450 enzyme expression strain, or it can represent the plasmid pRSFDuet-S1-FDR_FDI number, the wild enzyme SEQ ID NO:1 number, and the wild enzyme encoding gene SEQ ID NO:2 number.
[0060] Example 1: Cloning of wild-type P450 enzyme genes
[0061] Template: Sonoran Desert Bacillus genome
[0062] Upstream primer: ATGGCAAAATCAATTCAATCCGGCAATC,
[0063] Downstream primer: GCCGGTACGCCTTTTATCTCAATCATAA.
[0064] PCR reaction system (50 μL): 1 μL Sonora Desert Bacillus bacterial solution, 2 μL each of a pair of upstream and downstream primers (10 μM), Prime STAR Max DNA polymerase (2×) 25 μL, and sterile water to make up to 50 μL.
[0065] The PCR amplification procedure was as follows: (1) pre-denaturation at 98°C for 5 min; (2) denaturation at 98°C for 10 sec, (3) annealing at 56°C for 5 sec, and (4) extension at 72°C for 20 sec. Steps (2) to (4) were repeated 30 times, followed by a final extension at 72°C for 3 min. The PCR product was stored at 12°C.
[0066] The amplified PCR product was detected by 1% agarose gel electrophoresis and recovered and purified. The recovered product was sent to Sangon Biotech Co., Ltd. for sequencing, confirming that the target gene wild-type P450 enzyme gene was successfully obtained. The amino acid sequence of the wild-type P450 enzyme encoded by the gene is SEQ ID NO: 1.
[0067] In order to achieve the expression of wild-type P450 enzyme in Escherichia coli, the most commonly used host in the field of genetic engineering, the codon of the expression gene of the wild-type P450 enzyme was optimized, and its coding gene was designed. The nucleotide sequence can be SEQ ID NO: 2, and the whole gene synthesis was commissioned to Sangon Biotech Co., Ltd.
[0068] Example 2: Construction of wild-type P450 enzyme genetically engineered bacteria
[0069] Template: pRSFDuet-FDR_FDI
[0070] Upstream primer: TTATCTCAATCATAAGCGGCCGCATAATGCTTAAGTC,
[0071] Downstream primer: GCCTGCAGGTCGACAAGCTTATGGCAAAATCAATT.
[0072] PCR reaction system (50 μL): 1-50 ng of template, 2 μL (10 μM) of a pair of upstream and downstream primers, 25 μL of Prime STARMax DNA polymerase (2×), and sterile water to make up to 50 μL.
[0073] The PCR amplification procedure was as follows: (1) pre-denaturation at 98°C for 3 min; (2) denaturation at 98°C for 10 sec, (3) annealing at 56°C for 5 sec, and (4) extension at 72°C for 60 sec. Steps (2) to (4) were repeated 30 times, and the final step was extension at 72°C for 3 min. The PCR product was stored at 12°C.
[0074] The amplified PCR product was detected by 1% agarose gel electrophoresis and recovered and purified. The recovered and purified PCR product and the wild-type P450 enzyme encoding gene obtained in Example 1 were digested by T5 exonuclease for 3 to 5 minutes to obtain the recombinant expression vector pRSFDuet-S1-FDR_FDI.
[0075] Then, pRSFDuet-S1-FDR_FDI was electroporated into DH5α competent cells, evenly spread on LB solid medium containing 50μg / mL kanamycin, and inverted overnight in a 37°C incubator. Single clones were picked, verified by colony PCR, and sent to the company for sequencing. The strain with correct sequencing was cultured, the plasmid was extracted, and re-transformed into E.coli BL21(DE3) competent cells, cultured with culture medium at 37°C for 45-60min, spread on LB solid medium containing kanamycin, inverted overnight at 37°C, and colony PCR was used to verify the positive clones to obtain the recombinant transformant E.coliBL21(DE3) / pRSFDuet-S1-FDR_FDI strain for expressing wild-type P450 enzymes.
[0076] Example 3: Construction and screening of P450 enzyme S1 mutant library
[0077] Saturation mutations, especially amino acid replacements, were performed on some sites of the wild-type P450 enzyme S1, including K80, L83, T244, F388V and other computationally selected sites to construct a mutant library.
[0078] Template: pRSFDuet-S1-FDR_FDI
[0079] The primers used to construct some mutants such as M3 (K80F / T244A / F388V) and M4 (K80F / L83T / T244A / F388V) are as follows:
[0080] K80F-F: GGCGACATGGAAGGATTTAGCATATTGAC,
[0081] T244A-F: GTAGCGGGCAATGAAGCTACAACCAATT,
[0082] L83T-F:GAAGGAAAAAGCATAACTACGATGGACC,
[0083] F388V-R:GCGGACGCCGAAAACAACCGGGCTTTGA.
[0084] PCR reaction system (20 μL): 1-50 ng of template, 0.5 μL (10 μM) of a pair of upstream and downstream primers, 10 μL of PrimeSTAR Max DNA polymerase (2×), and sterile water to make up to 20 μL.
[0085] The PCR amplification procedure was as follows: (1) pre-denaturation at 98°C for 3 min; (2) denaturation at 98°C for 10 sec, (3) annealing at 56°C for 5 sec, and (4) extension at 72°C for 70 sec. Steps (2) to (4) were repeated 30 times, and the final step was extension at 72°C for 3 min. The PCR product was stored at 12°C.
[0086] The amplified PCR product was digested with Dpn I overnight in a 37°C water bath, inactivated at 80°C for 20 minutes, transferred to E.coliBL21 (DE3) competent cells, added with culture medium and revived at 37°C for 45-60 minutes, spread on LB solid culture medium containing kanamycin, inverted and cultured at 37°C overnight, picked a single clone and sent it to the company for sequencing, and used SnapGene biological analysis software to view the peak graph of the sequencing results to determine the correct mutation of the amino acid at the mutation site. The amino acid sequence of mutant M3 is SEQ ID NO:3, and the nucleotide sequence of the expressed gene is SEQ ID NO:4; the amino acid sequence of mutant M4 is SEQ ID NO:5, and the nucleotide sequence of the expressed gene is SEQ ID NO:6.
[0087] A mutant library of more than 600 mutants including M3 and M4 was constructed.
[0088] Example 4: Expression and purification of P450 enzyme S1 and its mutants
[0089] 4.1 Expression and purification of wild P450 enzyme S1 includes the following steps.
[0090] The expression strain of S1 obtained in Example 2 was inoculated into 2 mL of LB liquid medium containing kanamycin, and cultured at 37°C, 220 rpm for 5-6 h, and then inoculated into 100 mL of TB medium containing kanamycin at an inoculum of 1 v / v%. 600 When the concentration reached 0.6-0.8, IPTG was added at a final concentration of 0.2 mM, and the cells were induced and cultured in a shaker at 25°C and 200 rpm for 16 h. The cells were collected by centrifugation at 4000 rpm, and washed twice with 0.1 M, pH 8.0 potassium phosphate buffer to obtain resting cells, and then the obtained cells were resuspended with 0.1 M, pH 8.0 potassium phosphate buffer (containing 10 mM imidazole), ultrasonically broken in an ice bath, and the supernatant was collected by high-speed centrifugation, filtered with a 0.22 μm filter membrane, and the P450 enzyme S1 was purified using a Ni column.
[0091] 4.2 Express and purify mutants M3, M4 and other mutants respectively using the same method.
[0092] Example 5: Pure enzyme-catalyzed reaction with vitamin D3 as substrate
[0093] 5.1 Taking mutant M3 as an example, the reaction of VD3 conversion catalyzed by each mutant in the mutant library was examined.
[0094] Reaction system 250 μL: 0.5 g / L VD3, 2 μM pure enzyme, 8 μM FDR, 40 μM FDI, 2 mM NADPH, 5 wt% glucose, 5 U / mL glucose dehydrogenase (aladdin, G139687-1KU). Reaction temperature 30°C.
[0095] The reaction was monitored by HPLC. Figure 1 shown.
[0096] Depend on Figure 1 It can be seen that mutant M3 can convert vitamin D3, and about 60% of the substrate VD3 is converted into calcifediol. It is particularly important that VD3 almost generates the only hydroxylation product calcifediol, and there are no other hydroxylation reaction products, indicating that mutant M3 has a high degree of C25 hydroxylation position specificity.
[0097] 5.2 Comparison of the catalytic reactions of mutant M3, wild-type enzyme S1, and mutant M4
[0098] The catalytic reactions of wild enzyme S1 and other mutants such as M4 were compared according to the method in 5.1. The HPLC test results are as follows: Figure 2 shown.
[0099] Depend on Figure 2 It can be seen that the wild type S1 can hydroxylate VD3 to produce calcifediol and calcitriol, and the ratio of these two products is close to 1:1; the mutant M3 produces the only hydroxylated product calcifediol; the mutant M4 produces two products, calcifediol and calcitriol, but calcitriol is the main product, and the ratio of calcitriol in the two products is as high as more than 80%, indicating that the mutant M4 can simultaneously catalyze the hydroxylation of C1 and C25 positions, suggesting that the mutant M4 is more suitable for the production of calcitriol.
[0100] Example 6: Optimization of catalytic reaction conditions of mutant M3
[0101] The inventors also optimized the catalytic reaction conditions of mutant M3, including the solubilization of the substrate, reaction temperature, etc.
[0102] 6.1 Effect of different co-solvents on the reaction
[0103] The reaction was carried out in the reaction system of Example 5.1 using 2-hydroxypropyl-β-cyclodextrin, DMSO and ethanol as cosolvents respectively.
[0104] After 1 hour of reaction, samples were taken and tested by HPLC. The results were as follows: Figure 3As shown, it can be seen that the use of organic solvents such as ethanol and DMSO has a great influence on the reaction and will inhibit the reaction; when 2-hydroxypropyl-β-cyclodextrin is used, the reaction effect is best.
[0105] 6.2 Effect of different temperatures on the reaction
[0106] Using 2-hydroxypropyl-β-cyclodextrin as a cosolvent, the same reaction system was used and the reactions were carried out at 20°C, 25°C and 30°C respectively.
[0107] Comparing the three reaction temperatures of 20℃, 25℃ and 30℃, it was found that there was no obvious difference in the reaction at 25℃ and 30℃, but it was slightly worse at 20℃, indicating that the temperature within 20-25℃ will inhibit the reaction, and the temperature within 25℃-30℃ has no obvious effect on the reaction.
[0108] In summary, compared with the wild P450 enzyme S1, the mutant M3 (SEQ ID NO: 6) constructed and screened in the present invention can specifically catalyze the reaction of VD3 to produce calcifediol, and its C25 hydroxylation position specificity, i.e., product specificity, has been significantly improved, thereby enhancing the feasibility of industrial application.
[0109] References
[0110] 1. Scherlitz-Hofmann, I.; Dubs, M.; Prousa, R.; ,B.;Droescher,P.;Schick,H.; ,E.Synthesis of 25-hydroxyprovitamin D3 from ergosterol:amild method for cleavage of hetero Diels-Alder adducts leading to steroidal5,7-dienes[J].Synthesis,1999,8:1331-1334.
[0111] 2.Fuse,S.;Mifune,Y.;Tanabe,N.;Takahashi,T.Continuous-flow synthesis of activated vitamin D3and its analogues[J].Org.Biomol.Chem.,2012,10:5205-5211.
[0112] 3.Tanabe, M.; Johansson, J, G.; Yasuda, D. Method for preparing cholesta-5,7-diene-3,25-diol and analogs thereof[J].WO9321204.1993-10-28.
[0113] 4. Babot, ED; del Río, JC; Kalum, L.; Martínez, AT; Gutiérrez, A. SEQUENCE LISTING <110> Zhejiang Jinlangbo Pharmaceutical Co., Ltd. <120> A P450 enzyme for the synthesis of calcifediol <130> SHPI2110339 <160> 7 <170> SIPOSequenceListing 1.0 <210> 1 <211> 403 <212> PRT <213> Bacillus sonorensis <400> 1 Met Ala Lys Ser Ile Gln Ser Gly Asn Arg Tyr Ala Asn Trp Ile Pro 1 5 10 15 Met Lys Glu Ile Ser Ser Asn Glu Asp Gln Leu Phe Pro Phe Pro Ile 20 25 30 Tyr Asn Arg Leu Arg Lys Thr Ser Pro Val Arg Tyr Asp Gln Asp Arg 35 40 45 Lys Cys Trp Asp Ile Phe Ala Tyr Glu Asp Val Gln Tyr Val Leu Lys 50 55 60 Thr Pro Lys Leu Phe Ser Ser Lys Arg Gly Gly Asp Met Glu Gly Lys 65 70 75 80 Ser Ile Leu Thr Met Asp Pro Pro Arg His Thr Lys Met Arg Ala Ile 85 90 95 Val Asn Lys Ala Phe Thr Pro Lys Thr Val Lys Gln Leu Glu Ala His 100 105 110 Ile Glu Glu Val Thr Ala Phe Leu Leu Asp Glu Ala Lys Asp Lys Glu 115 120 125 Thr Phe Asp Met Val Glu Asp Leu Ala Gly Pro Leu Pro Val Ile Ile 130 135 140 Ile Ala Glu Leu Leu Gly Val Pro Thr Glu Asp Arg Arg Ile Phe Lys 145 150 155 160 His Tyr Ser Asp Ile Leu Val Ser Gly Ala Lys Asp Ser Ser Asp Glu 165 170 175 Ala Ile Lys Gln Met Asn Lys Gln Arg Glu Glu Gly Ser Glu Phe Leu 180 185 190 Arg Gly Tyr Phe Lys Thr Ile Ile Glu Glu Arg Lys Lys Asp Pro Lys 195 200 205 Glu Asp Leu Ile Ser Leu Leu Ile Gln Ala Glu Val Glu Gly Glu Arg 210 215 220 Leu Thr Glu Asp Glu Leu Leu Gly Phe Cys Thr Ile Leu Leu Val Ala 225 230 235 240 Gly Asn Glu Thr Thr Thr Asn Leu Ile Ala Asn Ala Val Arg Tyr Leu 245 250 255 Thr Glu Asp Pro Lys Thr Gln Glu Thr Val Arg Gly Asp Leu Ser Leu 260 265 270 Val Pro His Leu Val Glu Glu Thr Leu Arg Tyr Tyr Pro Pro Val Gln 275 280 285 Ala Ile Gly Arg Ile Ala Ala Gln Asp Thr Asp Ile Lys Gly Val Thr 290 295 300 Ile Pro Lys Gly Ser Thr Ile Ile Ser Trp Val Ala Ser Ala Asn Arg 305 310 315 320 Asp Glu Thr Lys Phe Asp Asp Pro Glu Ala Phe Arg Leu Asp Arg Lys 325 330 335 Ser Asn Pro His Met Ser Phe Gly Phe Gly Ile His Phe Cys Leu Gly 340 345 350 Ala Pro Leu Ala Arg Leu Glu Ala Asn Thr Ala Leu Ser Tyr Leu Leu 355 360 365 Arg His Ala Ser Ile Val Arg Glu Pro Ser Glu Lys Leu Glu Val Ile 370 375 380 Gln Ser Pro Phe Val Phe Gly Val Arg Arg Leu Pro Val Arg Leu Leu 385 390 395 400 Ser Gln Ser <210> 2 <211> 1212 <212> DNA <213> Artificial sequence <400> 2 atggcaaaat caattcaatc cggcaatcgt tatgcaaatt ggattccgat gaaagaaatc 60 agctcaaatg aagatcagct ttttccgttt ccgatttaca accggctccg aaagactagc 120 ccggtgcgtt atgatcaaga tcgaaagtgc tgggatatct ttgcctatga agatgttcag 180 tacgtattaa aaacgccaaa gcttttttca tcaaaacggg gcggcgacat ggaaggaaaa 240 agcatattga cgatggaccc gccaaggcat acaaaaatga gggcgatcgt caataaggct 300 tttaccccta agacagtgaa gcagctggaa gcgcacatcg aagaagtgac cgcttttctg 360 cttgatgaag cgaaagacaa agagacattt gatatggtcg aggatttggc cggaccgctt 420 ccggtgatta tcattgctga gctcctcggt gttcctaccg aagaccggcg catcttcaaa 480 cactattccg atattttggt ttcaggcgcg aaagacagct cagatgaagc catcaagcag 540 atgaacaagc aacgggaaga aggcagcgaa ttttaagag gctactttaa aacgatcatt 600 gaagaacgaa aaaaagacccc caaagaggat ttgattcgc ttttgattca ggctgaagtg 660 gaaggagaaa gattgacaga agacgaactg ttgggattct gcacgattct ttggtagcg 720 ggcaatgaaa cgacaaccaa tttaatagcc aatgccgtcc gctatctgac agaagatcca 780 aaaacgcagg agaccgtgag aggcgacctg tctctcgtcc ctcatctcgt tgaagaaacg 840 ctgcgctact accctcccgt gcaggcgatc ggccgcattg cagcccaaga cactgacatc 900 aagggtgtta cgattccaaa aggttctacc atcatcagct gggtggcttc agccaatcgg 960 gatgaaacaa aatttgatga tcctgaagcc tttaggcttg atcgcaaatc aaacccccat 1020 atgagtttcg ggtttggcat ccatttttgc ctgggagctc cctcgcccg tctggaagca 1080 aatactgcgc tctcatatct cttgcggcac gcttcaattg taagagaacc atcagagaag 1140 ctcgaagtga ttcaaagccc gtttgttttc ggcgtccgcc gcctgccggt acgcctttta 1200 tctcaatcat aa 1212 <210> 3 <211> 403 <212> PRT <213> Artificial Sequence <400> 3 Met Ala Lys Ser Ile Gln Ser Gly Asn Arg Tyr Ala Asn Trp Ile Pro 1 5 10 15 Met Lys Glu Ile Ser Ser Asn Glu Asp Gln Leu Phe Pro Phe Pro Ile 20 25 30 Tyr Asn Arg Leu Arg Lys Thr Ser Pro Val Arg Tyr Asp Gln Asp Arg 35 40 45 Lys Cys Trp Asp Ile Phe Ala Tyr Glu Asp Val Gln Tyr Val Leu Lys 50 55 60 Thr Pro Lys Leu Phe Ser Ser Lys Arg Gly Gly Asp Met Glu Gly Phe 65 70 75 80 Ser Ile Leu Thr Met Asp Pro Pro Arg His Thr Lys Met Arg Ala Ile 85 90 95 Val Asn Lys Ala Phe Thr Pro Lys Thr Val Lys Gln Leu Glu Ala His 100 105 110 Ile Glu Glu Val Thr Ala Phe Leu Leu Asp Glu Ala Lys Asp Lys Glu 115 120 125 Thr Phe Asp Met Val Glu Asp Leu Ala Gly Pro Leu Pro Val Ile Ile 130 135 140 Ile Ala Glu Leu Leu Gly Val Pro Thr Glu Asp Arg Arg Ile Phe Lys 145 150 155 160 His Tyr Ser Asp Ile Leu Val Ser Gly Ala Lys Asp Ser Ser Asp Glu 165 170 175 Ala Ile Lys Gln Met Asn Lys Gln Arg Glu Glu Gly Ser Glu Phe Leu 180 185 190 Arg Gly Tyr Phe Lys Thr Ile Ile Glu Glu Arg Lys Lys Asp Pro Lys 195 200 205 Glu Asp Leu Ile Ser Leu Leu Ile Gln Ala Glu Val Glu Gly Glu Arg 210 215 220 Leu Thr Glu Asp Glu Leu Leu Gly Phe Cys Thr Ile Leu Leu Val Ala 225 230 235 240 Gly Asn Glu Ala Thr Thr Asn Leu Ile Ala Asn Ala Val Arg Tyr Leu 245 250 255 Thr Glu Asp Pro Lys Thr Gln Glu Thr Val Arg Gly Asp Leu Ser Leu 260 265 270 Val Pro His Leu Val Glu Glu Thr Leu Arg Tyr Tyr Pro Pro Val Gln 275 280 285 Ala Ile Gly Arg Ile Ala Ala Gln Asp Thr Asp Ile Lys Gly Val Thr 290 295 300 Ile Pro Lys Gly Ser Thr Ile Ile Ser Trp Val Ala Ser Ala Asn Arg 305 310 315 320 Asp Glu Thr Lys Phe Asp Asp Pro Glu Ala Phe Arg Leu Asp Arg Lys 325 330 335 Ser Asn Pro His Met Ser Phe Gly Phe Gly Ile His Phe Cys Leu Gly 340 345 350 Ala Pro Leu Ala Arg Leu Glu Ala Asn Thr Ala Leu Ser Tyr Leu Leu 355 360 365 Arg His Ala Ser Ile Val Arg Glu Pro Ser Glu Lys Leu Glu Val Ile 370 375 380 Gln Ser Pro Val Val Phe Gly Val Arg Arg Leu Pro Val Arg Leu Leu 385 390 395 400 Ser Gln Ser <210> 4 <211> 1212 <212> DNA <213> Artificial Sequence <400> 4 atggcaaaat caattcaatc cggcaatcgt tatgcaaatt ggattccgat gaaagaaatc 60 agctcaaatg aagatcagct ttttccgttt ccgatttaca accggctccg aaagactagc 120 ccggtgcgtt atgatcaaga tcgaaagtgc tgggatatct ttgcctatga agatgttcag 180 tacgtattaa aaacgccaaa gcttttttca tcaaaacggg gcggcgacat ggaaggattt 240 agcatattga cgatggaccc gccaaggcat acaaaaatga gggcgatcgt caataaggct 300 tttaccccta agacagtgaa gcagctggaa gcgcacatcg aagaagtgac cgctttctg 360 cttgatgaag cgaaagacaa agagacattt gatatggtcg agatttggc cggaccgctt 420 ccggtgatta tcattgctga gctcctcggt gttcctaccg aagaccggcg catcttcaaa 480 cactattccg atattttggt ttcaggcgcg aaagacagct cagatgaagc catcaagcag 540 atgaacaagc aacgggaaga aggcagcgaa ttttaagag gctactttaa aacgatcatt 600 gaagaacgaa aaaaagacccc caaagaggat ttgattcgc ttttgattca ggctgaagtg 660 gaaggagaaa gattgacaga agacgaactg ttgggattct gcacgattct ttggtagcg 720 ggcaatgaag ctacaaccaa tttaatagcc aatgccgtcc gctatctgac agaagatcca 780 aaaacgcagg agaccgtgag aggcgacctg tctctcgtcc ctcatctcgt tgaagaaacg 840 ctgcgctact accctcccgt gcaggcgatc ggccgcattg cagcccaaga cactgacatc 900 aagggtgtta cgattccaaa aggttctacc atcatcagct gggtggcttc agccaatcgg 960 gatgaaacaa aatttgatga tcctgaagcc tttaggcttg atcgcaaatc aaacccccat 1020 atgagtttcg ggtttggcat ccatttttgc ctgggagctc ccctcgcccg tctggaagca 1080 aatactgcgc tctcatatct cttgcggcac gcttcaattg taagagaacc atcagagaag 1140 ctcgaagtga ttcaaagccc ggttgttttc ggcgtccgcc gcctgccggt acgcctttta 1200 tctcaatcat aa 1212 <210> 5 <211> 403 <212> PRT <213> Artificial Sequence <400> 5 Met Ala Lys Ser Ile Gln Ser Gly Asn Arg Tyr Ala Asn Trp Ile Pro 1 5 10 15 Met Lys Glu Ile Ser Ser Asn Glu Asp Gln Leu Phe Pro Phe Pro Ile 20 25 30 Tyr Asn Arg Leu Arg Lys Thr Ser Pro Val Arg Tyr Asp Gln Asp Arg 35 40 45 Lys Cys Trp Asp Ile Phe Ala Tyr Glu Asp Val Gln Tyr Val Leu Lys 50 55 60 Thr Pro Lys Leu Phe Ser Ser Lys Arg Gly Gly Asp Met Glu Gly Phe 65 70 75 80 Ser Ile Thr Thr Met Asp Pro Pro Arg His Thr Lys Met Arg Ala Ile 85 90 95 Val Asn Lys Ala Phe Thr Pro Lys Thr Val Lys Gln Leu Glu Ala His 100 105 110 Ile Glu Glu Val Thr Ala Phe Leu Leu Asp Glu Ala Lys Asp Lys Glu 115 120 125 Thr Phe Asp Met Val Glu Asp Leu Ala Gly Pro Leu Pro Val Ile Ile 130 135 140 Ile Ala Glu Leu Leu Gly Val Pro Thr Glu Asp Arg Arg Ile Phe Lys 145 150 155 160 His Tyr Ser Asp Ile Leu Val Ser Gly Ala Lys Asp Ser Ser Asp Glu 165 170 175 Ala Ile Lys Gln Met Asn Lys Gln Arg Glu Glu Gly Ser Glu Phe Leu 180 185 190 Arg Gly Tyr Phe Lys Thr Ile Ile Glu Glu Arg Lys Lys Asp Pro Lys 195 200 205 Glu Asp Leu Ile Ser Leu Leu Ile Gln Ala Glu Val Glu Gly Glu Arg 210 215 220 Leu Thr Glu Asp Glu Leu Leu Gly Phe Cys Thr Ile Leu Leu Val Ala 225 230 235 240 Gly Asn Glu Ala Thr Thr Asn Leu Ile Ala Asn Ala Val Arg Tyr Leu 245 250 255 Thr Glu Asp Pro Lys Thr Gln Glu Thr Val Arg Gly Asp Leu Ser Leu 260 265 270 Val Pro His Leu Val Glu Glu Thr Leu Arg Tyr Tyr Pro Pro Val Gln 275 280 285 Ala Ile Gly Arg Ile Ala Ala Gln Asp Thr Asp Ile Lys Gly Val Thr 290 295 300 Ile Pro Lys Gly Ser Thr Ile Ile Ser Trp Val Ala Ser Ala Asn Arg 305 310 315 320 Asp Glu Thr Lys Phe Asp Asp Pro Glu Ala Phe Arg Leu Asp Arg Lys 325 330 335 Ser Asn Pro His Met Ser Phe Gly Phe Gly Ile His Phe Cys Leu Gly 340 345 350 Ala Pro Leu Ala Arg Leu Glu Ala Asn Thr Ala Leu Ser Tyr Leu Leu 355 360 365 Arg His Ala Ser Ile Val Arg Glu Pro Ser Glu Lys Leu Glu Val Ile 370 375 380 Gln Ser Pro Val Val Phe Gly Val Arg Arg Leu Pro Val Arg Leu Leu 385 390 395 400 Ser Gln Ser <210> 6 <211> 1212 <212> DNA <213> Artificial Sequence <400> 6 atggcaaaat caattcaatc cggcaatcgt tatgcaaatt ggattccgat gaaagaaatc 60 agctcaaatg aagatcagct ttttccgttt ccgatttaca accggctccg aaagactagc 120 ccggtgcgtt atgatcaaga tcgaaagtgc tgggatatct ttgcctatga agatgttcag 180 tacgtattaa aaacgccaaa gcttttttca tcaaaacggg gcggcgacat ggaaggattt 240 agcataacta cgatggaccc gccaaggcat acaaaaatga gggcgatcgt caataaggct 300 tttaccccta agacagtgaa gcagctggaa gcgcacatcg aagaagtgac cgcttttctg 360 cttgatgaag cgaaagacaa agagacattt gatatggtcg aggatttggc cggaccgctt 420 ccggtgatta tcattgctga gctcctcggt gttcctaccg aagaccggcg catcttcaaa 480 cactattccg atattttggt ttcaggcgcg aaagacagct cagatgaagc catcaagcag 540 atgaacaagc aacgggaaga aggcagcgaa ttttaagag gctactttaa aacgatcatt 600 gaagaacgaa aaaaagacccc caaagaggat ttgattcgc ttttgattca ggctgaagtg 660 gaaggagaaa gattgacaga agacgaactg ttgggattct gcacgattct ttggtagcg 720 ggcaatgaag ctacaaccaa tttaatagcc aatgccgtcc gctatctgac agaagatcca 780 aaaacgcagg agaccgtgag aggcgacctg tctctcgtcc ctcatctcgt tgaagaaacg 840 ctgcgctact accctcccgt gcaggcgatc ggccgcattg cagcccaaga cactgacatc 900 aagggtgtta cgattccaaa aggttctacc atcatcagct gggtggcttc agccaatcgg 960 gatgaaacaa aatttgatga tcctgaagcc tttaggcttg atcgcaaatc aaacccccat 1020 atgagtttcg ggtttggcat ccatttttgc ctgggagctc cctcgcccg tctggaagca 1080 aatactgcgc tctcatatct cttgcggcac gcttcaattg taagagaacc atcagagaag 1140 ctcgaagtga ttcaaagccc ggttgttttc ggcgtccgcc gcctgccggt acgcctttta 1200 tctcaatcat aa 1212 <210> 7 <211> 5097 <212> DNA <213> Artificial Sequence <400> 7 ggggaattgt gagcggataa caattcccct gtagaaataa ttttgtttaa ctttaataag 60 gagatatacc atgggcagca gccatcacca tcatcaccac agccaggatc cgaattcgag 120 ctcggcgcgc ctgcaggtcg acaagctttg agcggccgca taatgcttaa gtcgaacaga 180 aagtaatcgt attgtacacg gccgcataat cgaaattaat acgactcact ataggggaat 240 tgtgagcgga taacaattcc ccatcttagt atattagtta agtataagaa ggagatatac 300 atatggcaga tctcaattgg atatcatgca gatcgcctct gatgtggagg cacctccacc 360 tgctcctgct aaggtagaga aacattcaaa gaaaatggag gaaggcatta cagttaacaa 420 gtttaagcct aagacccctt acgttggaag atgtcttctt aacaccaaaa ttactgggga 480 tgatgcaccc ggagagacct ggcacatggt tttttcccat gaaggagaga tcccttacag 540 agaagggcaa tccgttgggg ttattccaga tggggaagac aagaatggaa agccccataa 600 gttgagattg tactcgatcg ccagcagtgc tcttggtgat tttggtgatg ctaaatctgt 660 ttcgttgtgt gtaaaacgac tcatctacac caatgacgct ggagagacga tcaagggagt 720 ctgctccaac ttcttgtgtg acttgaaacc cggtgctgaa gtgaagttaa caggaccagt 780 tggaaggag atgctcatgc ccaaagaccc taacgcgaca attatcatgc ttggaactgg 840 aactgggatt gctcctttcc gttcattctt gtggaagatg ttcttcgaaa agcatgatga 900 ttacaagttt aacggcttgg cttggctttt cttgggtgta cccacaagca gttctcttct 960 ctacaaagag gaatttgaga agatgaagga aaaggctcca gacaacttca ggctggattt 1020 tgcagtgagc agagagcaaa ctaacgagaa agggagaag atgtacattc aaacccgaat 1080 ggcacaatac gcagttgagc tatgggaaat gttgaagaaa gataatactt atttctacat 1140 gtgtggtctc aagggaatgg aaaagggaat tgacgacatt atggtttcat tggctgctgc 1200 agaaggcatt gattggattg aatacaagag ccagttgaag aaggcagaac aatggaacgt 1260 tgaagtctac taaggtacct aaaggatat atcatggccg cctacaaggt gaccctggtg 1320 accccgaccg gcaacgtgga gttccagtgc ccggacgacg tgtacatcct ggacgccgca 1380 gaagaagg ggatcgacct gccgtacagc tgtcgcgcag gcagttgcag cagctgcgca 1440 1500 atcgacgagg gctgggttct gacatgcgcc gcctacccgg tgagcgatgt gaccatcgag 1560 acccacaaag aagaggagct gaccgcctaa ggccggccac gcgatcgctg acgtcggtac 1620 cctcgagtct ggtaaaaa ccgctgctgc gaaatttgaa cgccagcaca tggactcgtc 1680 tactagcgca gcttaattaa cctaggctgc tgccaccgct gagcaataac tagcataacc 1740 ccttggggcc tctaaacggg tcttgagggg ttttttgctg aaacctcagg catttgagaa 1800 gcacacggtc acactgcttc cggtagtcaa taaaccggta aaccagcaat agacataagc 1860 ggctatttaa cgaccctgcc ctgaaccgac gacaagctga cgaccgggtc tccgcaagtg 1920 gcacttttcg gggaaatgtg cgcggaaccc ctatttgttt attttctaa atacattcaa 1980 atatgtatcc gctcatgaat taattcttag aaaaactcat cgagcatcaa atgaaactgc 2040 aatttattca tatcaggatt atcaatacca tatttttgaa aaagccgttt ctgtaatgaa 2100 ggagaaaact caccgaggca gttccatagg atggcaagat cctggtatcg gtctgcgatt 2160 ccgactcgtc caacatcaat acaacctatt aatttcccct cgtcaaaaat aaggttatca 2220 agtgagaaat caccatgagt gacgactgaa tccggtgaga atggcaaaag tttatgcatt 2280 tctttccaga cttgttcaac aggccagcca ttacgctcgt catcaaaatc actcgcatca 2340 accaaaccgt tattcattcg tgattgcgcc tgagcgagac gaaatacgcg gtcgctgtta 2400 aaaggacaat tacaaacagg aatcgaatgc aaccggcgca ggaacactgc cagcgcatca 2460 acaatatttt cacctgaatc aggatattct tctaatacct ggaatgctgt tttcccgggg 2520 atcgcagtgg tgagtaacca tgcatcatca ggagtacgga taaaatgctt gatggtcgga 2580 agaggcataa attccgtcag ccagtttagt ctgaccatct catctgtaac atcattggca 2640 acgctacctt tgccatgttt cagaaacaac tctggcgcat cgggcttccc atacaatcga 2700 tagattgtcg cacctgattg cccgacatta tcgcgagccc atttataccc atataaatca 2760 gcatccatgt tggaatttaa tcgcggccta gagcaagacg tttcccgttg aatatggctc 2820 atactcttcc tttttcaata ttattgaagc atttatcagg gttattgtct catgagcgga 2880 tacatatttg aatgtattta gaaaaataaa caaataggca tgcagcgctc ttccgcttcc 2940 tcgctcactg actcgctacg ctcggtcgtt cgactgcggc gagcggtgtc agctcactca 3000 aaagcggtaa tacggttatc cacagaatca ggggataaag ccggaaagaa catgtgagca 3060 aaaagcaaag caccggaaga agccaacgcc gcaggcgttt ttccataggc tccgcccccc 3120 tgacgagcat cacaaaaatc gacgctcaag ccagaggtgg cgaaacccga caggactata 3180 aagataccag gcgtttcccc ctggaagctc cctcgtgcgc tctcctgttc cgaccctgcc 3240 gcttaccgga tacctgtccg cctttctccc ttcgggaagc gtggcgcttt ctcatagctc 3300 acgctgttgg tatctcagtt cggtgtaggt cgttcgctcc aagctgggct gtgtgcacga 3360 accccccgtt cagcccgacc gctgcgcctt atccggtaac tatcgtcttg agtccaaccc 3420 ggtaagacac gacttatcgc cactggcagc agccattggt aactgattta gaggactttg 3480 tcttgaagtt atgcacctgt taaggctaaa ctgaaagaac agattttggt gagtgcggtc 3540 ctccaaccca cttaccttgg ttcaaagagt tggtagctca gcgaaccttg agaaaaccac 3600 cgttggtagc ggtggttttt ctttatttat gagatgatga atcaatcggt ctatcaagtc 3660 aacgaacagc tattccgtta ctctagattt cagtgcaatt tatctcttca aatgtagcac 3720 ctgaagtcag ccccatacga tataagttgt aattctcatg ttagtcatgc cccgcgccca 3780 ccggaaggag ctgactgggt tgaaggctct caagggcatc ggtcgagatc ccggtgccta 3840 atgagtgagc taacttacat taattgcgtt gcgctcactg cccgctttcc agtcgggaaa 3900 cctgtcgtgc cagctgcatt aatgaatcgg ccaacgcgcg gggagaggcg gtttgcgtat 3960 tgggcgccag ggtggttttt cttttcacca gtgagacggg caacagctga ttgcccttca 4020 ccgcctggcc ctgagagagt tgcagcaagc ggtccacgct ggtttgcccc agcaggcgaa 4080 aatcctgttt gatggtggtt aacggcggga tataacatga gctgtcttcg gtatcgtcgt 4140 atcccactac cgagatgtcc gcaccaacgc gcagcccgga ctcggtaatg gcgcgcattg 4200 cgcccagcgc catctgatcg ttggcaacca gcatcgcagt gggaacgatg ccctcattca 4260 gcatttgcat ggtttgttga aaaccggaca tggcactcca gtcgccttcc cgttccgcta 4320 tcggctgaat ttgattgcga gtgagatatt tatgccagcc agccagacgc agacgcgccg 4380 agacagaact taatgggccc gctaacagcg cgatttgctg gtgacccaat gcgaccagat 4440 gctccacgcc cagtcgcgta ccgtcttcat gggagaaaat aatactgttg atgggtgtct 4500 ggtcagagac atcaagaaat aacgccggaa cattagtgca ggcagcttcc acagcaatgg 4560 catcctggtc atccagcgga tagttaatga tcagcccact gacgcgttgc gcgagaagat 4620 tgtgcaccgc cgctttacag gcttcgacgc cgcttcgttc taccatcgac accaccacgc 4680 tggcacccag ttgatcggcg cgagatttaa tcgccgcgac aatttgcgac ggcgcgtgca 4740 gggccagact ggaggtggca acgccaatca gcaacgactg tttgcccgcc agttgttgtg 4800 ccacgcggtt gggaatgtaa ttcagctccg ccatcgccgc ttccactttt tcccgcgttt 4860 tcgcagaaac gtggctggcc tggttcacca cgcgggaaac ggtctgataa gagacaccgg 4920 catactctgc gacatcgtat aacgttactg gtttcacatt caccaccctg aattgactct 4980 cttccgggcg ctatcatgcc ataccgcgaa aggttttgcg ccattcgatg gtgtccggga 5040 tctcgacgct ctcccttatg cgactcctgc attaggaaat taatacgact cactata 5097
Claims
1. A P450 enzyme mutant, It is characterized in that The amino acid sequence of the P450 enzyme mutant is SEQ ID NO:
3.
2. A gene encoding the P450 enzyme mutant as claimed in claim 1.
3. The gene according to claim 2, It is characterized in that The nucleotide sequence of the gene is SEQ ID NO:
4.
4. A plasmid comprising the gene as claimed in claim 3.
5. A microorganism for expressing the P450 enzyme mutant according to claim 1.
6. Use of the P450 enzyme mutant according to claim 1 or the microorganism according to claim 5 in producing calcifediol.
7. The use according to claim 6, It is characterized in that Vitamin D3 is used as a reaction substrate, and the P450 enzyme mutant as claimed in claim 1 or the microorganism as claimed in claim 5 is used to catalyze the C25 hydroxylation reaction to obtain calcifediol.
8. The use according to claim 7, It is characterized in that The reaction system includes a NADPH regeneration system.
Citation Information
Cited By
Method for synthesizing calcifediol using peroxidase
CN116240246B
